Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Green tea extract shows promise for gut health in metabolic syndrome

NCT ID NCT03973996

Disease control Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking green tea extract for one month could improve gut health and reduce inflammation in people with metabolic syndrome and in healthy adults. Participants took either the extract or a placebo for a month, then switched. The study measured markers of inflammation and gut barrier function in blood and urine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

46 people

The number who actually took part.

Started

Jul 2019

Finished

Mar 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: Individuals with ≥3 of the following established criteria for metabolic syndrome: * Fasting glucose 100-126 mg/dL * Waist circumference \>89/\>102 cm for females/males * HDL-C \<50/\<40 mg/dL for females/males * Triglyceride \>150 mg/dL * Blood pressure \>130/85 mmHg Healthy adults: * Body weight 19-25 kg/m2 * Fasting glucose \<100 mg/dL * HDL-C \>50/\>40 mg/dL for females/males * Triglyceride \<150 mg/dL * Blood pressure \<120/80 mmHg Exclusion criteria: * Concurrent tea consumption * Use of dietary supplements, prebiotics, or probiotics * Use of antibiotics or antiinflammatory agents * History of liver disease, cardiovascular disease, hypertension (blood pressure \>140/90 mmHg), or cancer * History of gastrointestinal disorders, chronic diarrhea, or surgeries * Hemochromatosis * Parkinson's disease * Use of medications to manage diabetes, hypertension, or hyperlipidemia * Use of antipsychotic medications \[Clozapine, lithium, Diazepam\] * Use of blood thinning medications \[Warfarin\] * Use of high blood pressure medications \[nadolol\] * Use of monoamine oxidase inhibitors \[selegiline\] * Alcohol consumption \>2 drinks/d * Smoking tobacco * Vegetarian * Pregnancy, lactation, or recent changes in birth control use for women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dysbiosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Dysbiosis Endotoxemia Inflammation inflammatory disease metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dysbiosis Endotoxemia Inflammation Metabolic syndrome

Contacts and locations

Locations

  • The Ohio State University

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.